The most common adverse effects in a study investigating ramucirumab monotherapy were [[diarrhoea]] (14% of patients, as compared to 9% under [[placebo]]), [[hyponatraemia]] (low blood [[sodium]] levels; 6% versus 2%), headache (9% versus 3%), and high blood pressure (16% versus 8%).<ref name="Drugs.com">{{Drugs.com|pro|cyramza}} on Cyramza.</ref>

 

